Elisabetta Mercuri

Elisabetta Mercuri

Auto-generated profile, based on publicly available information

Elisabetta Mercuri

Robert Koch Institute

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in International Journal of Public Health
Verified
Journal Article
Open access
SBSusanne Bartig
Susanne Bartig
FBFlorian Beese
Florian Beese
BWBenjamin Wachtler
Benjamin Wachtler
MGMarkus M. Grabka
Markus M. Grabka
EMElisabetta Mercuri
Elisabetta Mercuri
JHJens Hoebel
Jens Hoebel
Objective:To evaluate the socioeconomic patterns of SARS-CoV-2 antigen contacts through infection, vaccination or both (“hybrid immunity”) after 1 year of vaccination campaign.Methods:Data were derived from the German seroepidemiological Corona Monitoring Nationwide study (RKI-SOEP-2;n= 10,448; November 2021–February 2022). Combining serological and self-report data, we estimated adjusted prevalence ratios (PR) of SARS-CoV-2 infection, COVID-19 vaccination, basic immunization (at least two SARS-CoV-2 antigen contacts through vaccination and/or infection), and three antigen contacts by education and income.Results:Low-education groups had 1.35-times (95% CI 1.01–1.82) the risk of SARS-CoV-2 infection compared to high-education groups. COVID-19 vaccination (at least one dose) and basic immunization decreased with lower education and income. Low-education and low-income groups were less likely to have had at least three antigen contacts (PR low vs. high education: 0.74, 95% CI 0.65–0.84; PR low vs. high income: 0.66, 95% CI 0.57–0.77).Conclusion:The results suggest a lower level of protection against severe COVID-19 for individuals from low and medium socioeconomic groups. Pandemic response and vaccination campaigns should address the specific needs and barriers of these groups.

31 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
EMElisabetta Mercuri
Elisabetta Mercuri
LSLorenz Schmid
Lorenz Schmid
CPChristina Poethko-Müller
Christina Poethko-Müller
MSMartin Schlaud
Martin Schlaud
CKCânâ Kußmaul
Cânâ Kußmaul
RGRKI-SOEP-2 Study Group
RKI-SOEP-2 Study Group
Summary: Background: The first wave of the Corona Monitoring Nationwide (RKI-SOEP) Study drawn from the German Socio-Economic Panel proved a low pre-vaccine SARS-CoV-2 seroprevalence in the German adult population of 2.1%. Methods: In this second wave of the study (RKI-SOEP-2, November 2021-March 2022), we used combined serological and self-reported data on infection and vaccination to estimate the prevalence of SARS-CoV-2-specific anti-spike and/or anti-nucleocapsid IgG antibodies (combined seroprevalence), past infection, and basic immunization in individuals aged 14+. Findings: Combined seroprevalence was 90.7% (95% CI 89.7% - 91.6%) without correction for antibody waning and 94.6% (95% CI 93.6% - 95.7%) with correction. While 1 in 10 individuals had been infected (9.9%, 95% CI 9.0% - 10.9%), 9 in 10 had at least a basic immunization (90%, 95% CI 88.9%-90.9%). Population-weighted estimates differed by age, region, and socioeconomic deprivation. Infection-induced seroprevalence with correction for antibody waning was 1.55 (95% CI 1.3 - 1.8) times higher than the cumulative proportion based on national surveillance data. Interpretation: At the beginning of the SARS-CoV-2-Omicron wave, the vast majority of the population had been vaccinated, infected, or both. Our results show how large-scale vaccination, but not a high infection rate, was able to fill the immunity gap, especially in older individuals (aged 65+) who are known to be at higher risk of severe COVID-19. Our data point towards a targeted demographically and regionally stratified mitigation strategy, to optimize future pandemic mitigation efforts.

25 October 2022 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
EME E Mercuri
E E Mercuri
CPC Poethko-Müller
C Poethko-Müller
ARA Schaffrath Rosario
A Schaffrath Rosario
LSL Schmid
L Schmid
MSM Schlaud
M Schlaud
AGA A Gößwald
A A Gößwald
Introduction: The first wave of the “Corona Monitoring bundesweit” (RKI-SOEP) study showed that shortly before the start of the German vaccination program only about 2% of adults (> 18 years) had already experienced SARS-CoV-2 infection and more than half of these cases had been detected and notified. The objectives of the second wave of this study are to further investigate the spread of SARS-CoV-2 in Germanýs population aged over 14 years. It aims to determine the seroprevalence of infection- and vaccine-induced IgG antibodies against SARS-CoV-2. Finally, it examines health, demographic and socioeconomic risk and protective factors for infection and vaccine acceptance. Methods: From November 2021 to February 2022, the second wave of this cross-sectional study collected biospecimens (capillary blood samples) and interview data, including information on infection and vaccination, from a nationwide population sample drawn from the German Socio-Economic Panel (SOEP). The dried self-collected blood samples were then analyzed for the detection of SARS-CoV-2 IgG antibodies by Euroimmun ELISA assay. Results: Based on preliminary, unweighted data of around 11,000 participants aged >14 years (52% response rate), we expect the final seroprevalence of SARS-CoV-2 antibodies to be in the range of 80 to 90%. Thus, around 10 to 20% of the German population may still be susceptible to a severe disease progression because they are neither infected nor vaccinated. Final results, weighted for non-response and adjusted for test sensitivity and specificity, will be presented. Conclusions: The RKI-SOEP-2 study will be pivotal in both, contributing to an improved understanding of SARS-CoV-2 propagation in different regional and sub-group settings and in identifying vulnerable target groups that need to be protected against future infections. Key messages: • Dried blood self-sampling in a nationwide sample is a robust tool to estimate seroprevalence at a population level. • As of February 2022, presumably 80 to 90% of the German population has previously been infected and/or vaccinated against SARS-CoV-2.